Reuters: Regulatory News: Japan approves lung drugs from GSK/Theravance and SkyePharma

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Make Money From Your Roof We are paying to help homeowners profit from producing solar power. Find out if your home qualifies for our program today. Sign up! From our sponsors

Japan approves lung drugs from GSK/Theravance and SkyePharma Sep 20th 2013, 07:42 LONDON, Sept 20 | Fri Sep 20, 2013 3:42am EDT LONDON, Sept 20 (Reuters) - GlaxoSmithKline and Theravance's new inhaled lung drug Relvar has been approved in Japan, a day after winning a positive recommendation in Europe. The Japanese Ministry of Health, Labour and Welfare also approved Skyepharma's Flutiform lung treatment, which will be sold by Kyorin Pharmaceutical. Under the terms of a 2002 agreement, Theravance is obliged to make a milestone payment of $10 million to GSK following the Japanese approval, GSK said on Friday. SkyePharma, meanwhile, said it would receive a milestone of "several million U.S. dollars" from Kyorin. The Japanese authorisation for Relvar covers use of the drug, which is inhaled through a palm-sized device called Ellipta, for the treatment of asthma but not chronic obstructive pulmonary disease (COPD). The medicine was approved in the United States in May for treating COPD but not asthma, while in Europe the recommendation from the European Medicines Agency is that it be used for both conditions. Relvar consists of a corticosteroid to reduce inflammation and a novel long-acting beta-agonist (LABA), which is designed to open the airways. It is one of two new medicines that GSK is relying on to reinvigorate its respiratory business as the company's $8 billion-a-year blockbuster Advair faces the threat of generic competition in the years ahead. The other key new lung drug is Anoro, which combines a LABA therapy with a long-acting muscarinic receptor antagonist (LAMA). Anoro is still awaiting approval. Link this Share this Digg this Email Reprints

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions